TITLE

Gardasil

PUB. DATE
February 2011
SOURCE
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the approval of Gardasil from Merck & Co. Inc., designed for the prevention of anal cancer caused by human papillomavirus (HPV) applicable for patient ages 9 to 26.
ACCESSION #
58103695

 

Related Articles

  • Merck & Co announces launch of collaborative cancer trials network.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p17 

    The article announces the launch of the collaborative trials network by Merck and Co. Inc. that will focus on the development of Merck drug and vaccine candidates investigated for the treatment and prevention of cancer.

  • Pfizer, Merck Explore Cancer Therapies.  // Chain Drug Review;2/17/2014, Vol. 36 Issue 4, p46 

    The article reports that drug manufactuirng companies Pfizer Inc. and a pair of Merck & Co. subsidiaries have collaborated to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two oncology assets of Pfizer.

  • Merck's Free Radical. Herper, Matthew // Forbes Asia;11/10/2008, Vol. 4 Issue 19, p114 

    The article focuses on the efforts of cancer specialist Stephen Friend at Merck & Co. Inc. to create an open-to-the-public database that will include every cancer drug and every patient and how that patient is doing with a view to raise the success rate of the cancer treatment. It states that by...

  • Novel PD-1 antibody induced response in previously treated NSCLC. Todak, Alexandra // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p22 

    The article discusses the results of a randomized clinical trial which revealed that the novel PD-1 antibody MK3475 developed by pharmaceutical firm Merck & Co. was able to induce durable objective responses in patients with previously-treated non-small cell lung cancer (NSCLC).

  • Endocyte. Investor's Business Daily // Investors Business Daily;5/ 5/2014, pA02 

    The article reports on the results of the clinical trials on Vynfinit, a drug agent for ovarian cancer treatment, which has been initiated by pharmaceutical firms Endocyte in partnership with Merck & Co. Inc.

  • BRAND OF THE YEAR. Herskovits, Beth // Pharmaceutical Executive;Feb2007, Vol. 27 Issue 2, p58 

    The article discusses the vaccine Gardasil launched by Merck for human papillomavirus (HPV) in the U.S. Gardasil is a first cancer vaccine that has been chosen as the 2006 Brand of the Year for it represents the connection between science, commercialization and humanity that stand for great...

  • Colorectal Cancer News Headlines May 15, 2003--June 14, 2003.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p12 

    Presents news updates concerning treatment for colorectal cancer, compiled as of June 14, 2004. Cell Therapeutics' plan to advance its polyglutamate camptothecin drug to phase II clinical trials; Demonstration that Avastin plus chemotherapy extend the survival of colorectal cancer patients in...

  • Pfizer's Celebrex may increase cardiovascular risk.  // PharmaWatch: Cancer;Feb2005, Vol. 4 Issue 2, p19 

    The article focuses on the cardiovascular risk of cancer drug Celebrex from Pfizer Inc. Celebrex, as a selective COX-II inhibitor, functions by reducing prostaglandin production at the site of inflammation. COX-II expression is heightened in pre-cancerous cells which led to the use of Celebrex...

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Jun2007, Vol. 6 Issue 6, p6 

    The article offers news briefs related to cervical cancer treatment. Merck & Co Inc. has applied to expand the labeling of its cervical cancer vaccine Gardasil to also include vaginal and vulvar cancers. GlaxoSmithKline's Cervarix, a cervical cancer candidate vaccine, showed efficacy in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics